GeneDx Investors Face August Deadline in Securities Class Action

The litigation, captioned Taher Basma v. GeneDx Holdings Corp., centers on allegations that the genetic testing firm issued misleading statements regarding its $51 million acquisition of Fabric Genomics. While GeneDx touted the deal as a gateway to scalable revenue and AI-driven growth, the complaint alleges that leadership failed to disclose significant viability issues surrounding the acquired company.

Market confidence collapsed on May 4, 2026, when GeneDx reported its first-quarter results. The company revealed a sharp decline in adjusted gross margins and lower-than-expected reimbursement rates. Most notably, GeneDx disclosed a $31.3 million impairment loss tied to Fabric—nearly the entire initial cash outlay for the acquisition. Following the disclosure, the company’s share price plummeted by more than 49%. Investors seeking to discuss their legal rights or participate in the action may contact Kessler Topaz Meltzer & Check, LLP, which is representing potential claimants.